Literature DB >> 23955198

Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas.

Edit Bárdi1, Mónika Csóka, Ildikó Garai, István Szegedi, Judit Müller, Tamás Györke, Kornélia Kajáry, Karolina Nemes, Csongor Kiss, Gábor Kovács.   

Abstract

The aim of the study was to assess sensitivity and specificity of FDG-PET/CT in different forms of childhood cancer. We retrospectively evaluated the results dedicated of 162 FDG-PET/CT examinations of 86 children treated with: Hodgkin lymphoma (HL; n = 31), non-Hodgkin lymphoma (NHL; n = 30) and other high grade solid tumors (n = 25). Patients were admitted and treated in two departments of pediatric hematology and oncology in Hungary. FDG-PET/CT was performed for staging (n = 25) and for posttreatment evaluation (n = 137). Imaging was performed in three FDG-PET/CT Laboratories, using dedicated PET/CT scanners. False positive results were defined as resolution or absence of disease progression over at least 1 year on FDG-PET/CT scans without any intervention. In some cases histopathological evaluation of suspicious lesions was performed. Fals negative results were defined as negative FDG-PET/CT results in case of active malignancy. Positive predictive values (PPV) and negative predictive values (NPV) were calculated. NPV was 100%. The highest PPV was observed in high grade solid tumors (81%), followed by HL (65%) and NHL (61%). There was a major difference of PPV in different histological types of HL (50% in HL of mixed-cellularity subtype, 90% in nodular sclerosing, and 100% in lymphocyte-rich and lymphocyte depleted HL). We treated one patient with nodular lymphocyte predominant HL, who had 5 false positive FDG-PET/CT results. PPV of T- and B-lineage NHL were similar (60% and 62%, respectively). We observed an interesting difference of PPV in different stages of HL and NHL. In HL PPV was higher in early than in advanced disease forms: 66% in stage II HL and 60% in stage III HL, whereas there was an inverse relationship between PPV and disease stages in NHL 0% in stage I and II patients, 67% in stage III and 100% in stage IV patients. PPV was lower in males (54%) than in females (65%). PPV were 64% vs. 58% in patients under vs. over 10 years of age. Negative FDG-PET/CT results during follow-up reliably predict the absence of malignancy. Positive FDG-PET/CT scan results in general have a low PPV. The relatively high PPV in patients with histologically proven high grade solid tumors, advanced stages of NHL and with nodular sclerosing, lymphocyte-rich and lymphocyte depleted subtypes of HL warrant a confirmation by biopsy, whereas the watch-and-wait approach can be used in other forms of childhood cancer patients with a positive FDG-PET/CT result in course of follow-up examinations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955198     DOI: 10.1007/s12253-013-9676-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  19 in total

1.  18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging.

Authors:  Kevin London; Siobhan Cross; Ella Onikul; Luciano Dalla-Pozza; Robert Howman-Giles
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-17       Impact factor: 9.236

2.  Is PET/CT necessary in paediatric oncology? For.

Authors:  Christiane Franzius; Kai Uwe Juergens; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

3.  PET/CT with diagnostic CT in the evaluation of childhood sarcoma.

Authors:  Christiane Franzius; Kai U Juergens; Josef Vormoor
Journal:  AJR Am J Roentgenol       Date:  2006-02       Impact factor: 3.959

Review 4.  PET imaging for pediatric oncology: an assessment of the evidence.

Authors:  Carol Portwine; Christopher Marriott; Ronald D Barr
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

5.  Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.

Authors:  Cécile Colavolpe; Eric Guedj; Serge Cammilleri; David Taïeb; Olivier Mundler; Carole Coze
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

6.  The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors.

Authors:  Dae-Weung Kim; Sang-Ah Jung; Chang-Guhn Kim; Soon-Ah Park
Journal:  Clin Nucl Med       Date:  2010-06       Impact factor: 7.794

7.  Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.

Authors:  Melissa M Rhodes; Dominique Delbeke; James A Whitlock; William Martin; John F Kuttesch; Haydar A Frangoul; Sadhna Shankar
Journal:  J Pediatr Hematol Oncol       Date:  2006-05       Impact factor: 1.289

Review 8.  PET/CT in the evaluation of childhood sarcomas.

Authors:  M Beth McCarville; Ryan Christie; Najat C Daw; Sheri L Spunt; Sue C Kaste
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

9.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.

Authors:  Douglas S Hawkins; Joseph G Rajendran; Ernest U Conrad; James D Bruckner; Janet F Eary
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

10.  Diagnostic value of PET/CT for the staging and restaging of pediatric tumors.

Authors:  Margit Kleis; Heike Daldrup-Link; Katherine Matthay; Robert Goldsby; Ying Lu; Tibor Schuster; Carole Schreck; Philip W Chu; Randall A Hawkins; Benjamin L Franc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-22       Impact factor: 9.236

View more
  2 in total

1.  Use of PET/CT instead of CT-only when planning for radiation therapy does not notably increase life years lost in children being treated for cancer.

Authors:  Josefine S Kornerup; Patrik Brodin; Charlotte Birk Christensen; Thomas Björk-Eriksson; Anne Kiil-Berthelsen; Lise Borgwardt; Per Munck Af Rosenschöld
Journal:  Pediatr Radiol       Date:  2014-11-07

2.  PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy.

Authors:  J S Kornerup; N P Brodin; T Björk-Eriksson; C Birk Christensen; A Kiil-Berthelsen; M C Aznar; C Hollensen; E Markova; P Munck Af Rosenschöld
Journal:  Br J Radiol       Date:  2014-12-12       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.